---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117946"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:00:49.782834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D

## Summary
- First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.
- Islet engraftment 3-5x higher than comparable subjects on tacrolimus-based immunosuppression, suggesting less toxicity to transplanted cells.
- Treatment was generally well tolerated with no unexpected adverse events or severe hypoglycemic episodes.
- Data to be presented at IPITA/HSCI/Breakthrough T1D Stem Cells Summit on Oct 29, 2024.

## SEC filing metadata
- accession: 0000950170-24-117946
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024117946/0000950170-24-117946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024117946/eldn-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117946
- JSON: https://secwatch.observer/filing/0000950170-24-117946.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.